Skip to main content

Garren Hideki's Form 4 filing

Prothena Corp Public Ltd Co (PRTA) · filed Sep 13, 2023

Accession no.
0000905148-23-000919
Filed
Sep 13, 2023
Trade date
Sep 13, 2023
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $111.0K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Garren HidekiCIK 0001854126Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 13, 2023Ordinary Shares, par value $0.01 per shareMOption exerciseAcquired+2,000$24.90+$49,8002,000Direct
Sep 13, 2023Ordinary Shares, par value $0.01 per shareSSaleDisposed−2,000$55.48F2−$110,9600Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 13, 2023Ordinary SharesMOption exerciseDisposed−2,000$0.00$0192,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades in prices ranging from $54.995 to $55.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)